Supplement AERs Require Less Forgiving Risk/Benefit Calculation - FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA applies a lower tolerance for risk in evaluating serious adverse event reports for dietary supplements than for drug AERs because of the "uncertainty" surrounding supplement products, an agency official says